MG
EVFM

Michael Gelband’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Michael Gelband’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,892
Closed -$134K – 2875
2021
Q2 		$134K Buy
7,892
+6,889
+687% +$131K ﹤0.01% 2088
2021
Q1 		$26K Buy
+1,003
New +$45.6K ﹤0.01% 2053
2020
Q2 		– Sell
-1,358
Closed -$108K – 2124
2020
Q1 		$108K Buy
+1,358
New +$109K 0.01% 883

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Michael Gelband's EVFM Position: Q3 2021 in Review

Michael Gelband sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 7,892 shares — an estimated $134K sold.

Michael Gelband first reported a position in EVFM in Q1 2020 and held it in 3 quarters. The position peaked at $134K in Q2 2021. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

  • Michael Gelband reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 7,892 Evofem Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $134K.
  • Michael Gelband first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Michael Gelband's Evofem Biosciences, Inc. Common Stock position peaked at $134K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.